In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats
Search for other papers by Christine Brideau in
Current site
Google Scholar
PubMed
Present address is Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA 91320.
Search for other papers by Carlo Van Staden in
Current site
Google Scholar
PubMed
Search for other papers by Chi Chung Chan in
Current site
Google Scholar
PubMed
Abstract
Objective—To determine potency and selectivity of nonsteroidal anti-inflammatory drugs (NSAID) and cyclooxygenase- (COX-) specific inhibitors in whole blood from horses, dogs, and cats.
Sample Population—Blood samples from 30 healthy horses, 48 healthy dogs, and 9 healthy cats.
Procedure—Activities of COX-1 and COX-2 were determined by measuring coagulation-induced thromboxane B2 and lipopolysaccharide-induced prostaglandin E2 concentrations, respectively, in whole blood with and without the addition of various concentrations of phenylbutazone, flunixin meglumine, ketoprofen, diclofenac, indomethacin, meloxicam, carprofen, 5-bromo-2[4-fluorophenyl]-3-[4- methylsulfonylphenyl]-thiophene (DuP 697), 5,5- dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furan one (DFU), 3-(3,4-difluorophenyl)- 4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone (MF-tricyclic), and celecoxib. Potency of each test compound was determined by calculating the concentration that resulted in inhibition of 50% of COX activity (IC50). Selectivity was determined by calculating the ratio of IC50 for COX-1 to IC50 for COX-2 (COX-1/COX-2 ratio).
Results—The novel compound DFU was the most selective COX-2 inhibitor in equine, canine, and feline blood; COX-1/COX-2 ratios were 77.5, 74, and 69, respectively. Carprofen was the weakest inhibitor of COX-2, compared with the other COX-2 selective inhibitors, and did not inhibit COX-2 activity in equine blood. In contrast, NSAID such as phenylbutazone and flunixin meglumine were more potent inhibitors of COX-1 than COX-2 in canine and equine blood.
Conclusions and Clinical Relevance—The novel COX-2 inhibitor DFU was more potent and selective in canine, equine, and feline blood, compared with phenylbutazone, flunixin meglumine, and carprofen. Compounds that specifically inhibit COX-2 may result in a lower incidence of adverse effects, compared with NSAID, when administered at therapeutic dosages to horses, dogs, and cats. (Am J Vet Res 2001;62:1755–1760)
| All Time | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 165 | 0 | 0 |
| Full Text Views | 2856 | 2242 | 49 |
| PDF Downloads | 712 | 241 | 22 |
